TUMOUR DNA BIOMARKERS – TISSUE


  • DNA + RNA biomarkers in formalin fixed, paraffin embedded tumour tissue
  • Designed by Illumina
  • Analytical validation, clinical validation and testing at the Peter MacCallum Cancer Centre, Melbourne
  • 523 genes:
    • single nucleotide variations (SNVs)
    • insertions/deletions (indels)
    • copy number alterations (CNAs)
    • fusions
    • microsatellite instability status (MSI)
  • Tumour agnostic biomarkers:
    • Tumour Mutation Burden (TMB)
    • MSI status
    • NTRK 1-3
  • Published quality metrics:
    • robust assay with low failure rate (<1%)
    • high sensitivity across range of mutant allele frequencies
    • very high specificity
  • Clinical reporting of all FDA/NCCN approved biomarkers
  • Clinical trial availability reported in each case
  • MDM review of all cases with option for referring clinician to participate

Insurance cover


null

Please discuss with your
Insurance Provider
Tests covered by the PartnersLife Cancer Testing Benefit schedule

Our Partners


Order a test


For patients:

  • Contact your Doctor to arrange testing

For clinicians:

  • Download and complete the test requisition form. Please provide patient contact details (email and mobile number)
  • Scan and email to richard@sequenca.nz with a copy of the histology report
  • Sequenca Genetics will obtain slides and tissue blocks, select relevant block, and send to PeterMac for testing